Genmab — Maj 2016
-
Daratumumab is basically being combined with just about anything that you can think of in the context of phase III studies http://global.onclive.com/insights/Immunotherapy-in-multiple-myeloma/antibodies-in-combination-therapy-for-myeloma
-
-
Vitae har med en markedsværdi på 200 millioner dollar et stykke vej til Anacors, men har med deres RORgt inhibitor sigte mod psoriasis og med LXR mod AD. Begge stoffer har chance for at blive first in class, så det siger lidt om mulighederne hvis de skulle gå hen og få succes. Lang vej endnu men alligevel.........
-
Anonyme burde læse denne her: http://www.daytrader.dk/kobssignal-genmab-brudt-1000/?utm_source=e-mail&utm_medium=e-mail&utm_campaign=e-mail
-
Novartis splits drugs business into two, pharma chief to leave
ZURICH/LONDON (Reuters) - Novartis is splitting its pharmaceuticals division into two business units, one focused on cancer and the second on other drugs, while switching out its current pharma head in the second high-profile management reshuffle this year. David Epstein, the American head of Novartis Pharmaceuticals and a 27-year veteran with the group, will leave the company to "explore new challenges from the U.S.", Novartis said. Novartis' reorganization of its main drugs unit, which accounts for about two-thirds of its $49 billion in annual sales, shows the growing importance of oncology to the company, after it bought GSK's marketed cancer drugs for $16 billion last year.
Yahoo Finance (finance.yahoo.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind